Trial
NCT02258464
Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Bayer
Collaborators
—
Condition
Breast Neoplasms
Intervention
Radium-223 dichloride (Xofigo, BAY88-8223)
Why stopped
Due to lower than expected recruitment since the start of study
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-08-10